Kuzmanovic, Milos (6602721300)Milos (6602721300)KuzmanovicJurisic, Vladimir (6603015144)Vladimir (6603015144)Jurisic2025-06-122025-06-122012https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875812564&partnerID=40&md5=f045e527886b1dbda547e6edca7f0923https://remedy.med.bg.ac.rs/handle/123456789/9834We report the successful use of rituximab as single treatment modality in a five-month-old boy with fulminant warm autoantibody autoimmune hemolytic anemia, resistant to standard treatment. On admission, laboratory tests showed a profound anemia with a hemoglobin of 2.6 g/dL. Indirect and direct antiglobulin tests were strongly positive, and nonspecific IgG autoantibodies were detected. Two days of intravenous corticosteroids (methylprednisolone 4mg/kg) and immunoglobulins (1g/kg) did not halt the hemolysis and the infant was severely transfusion-dependent. Rituximab 375mg/sq m weekly was given for 4 weeks, the hepatosplenomegaly gradually regressed, the lymphocytes normalized and he is free from hemolysis two years after treatment.